← All indications
Anemia, Refractory
A severe sometimes chronic anemia, usually macrocytic in type, that does not respond to ordinary antianemic therapy.
Subtype terms (1)
More specific conditions that are subtypes of Anemia, Refractory in the MeSH hierarchy.
- Anemia, Refractory, with Excess of Blasts
7 drugs (3 approved, 4 experimental)
Drugs by status
Phase 3 trials (20)
Phase 2 trials (25)
- thalidomide
- temsirolimus
- clofarabine
- entinostat
- tacrolimus
- Filgrastim
- bc8
- montanide isa51
- ibrutinib
- pr1 peptide
- zarnestra
- romiplostim
- cyclosporine
- mycophenolate
- abatacept
- allogeneic lymphocytes
- vorinostat
- autologous umbilical cord blood
- thiotepa
- melphalan
- zanubrutinib
- lv-nyeso tcr /sr39tk pbsc
- rv-nyeso tcr pbmc
- t lymphocytes
- autologous hematopoietic stem cells
Phase 1 trials (14)
Other trials (3)
Organizations
Organization Involved with Phase 3 Indications (16)
- Eli Lilly
- Onconova Therapeutics, Inc.
- Kanisa Pharmaceuticals
- National Cancer Institute (NCI)
- University of London
- Eastern Cooperative Oncology Group
- Gottfried Wilhelm Leibniz Universität Hannover
- Indiana University
- University of Hamburg
- University of Witten/Herdecke
- University of Ulm
- University of Freiburg
- Ludwig Maximilians University
- J. W. Goethe University
- Ev. Krankenhaus Essen-Werden
- Ghent University
Organization Involved with Phase 2 Indications (16)
- Seattle Genetics
- IGF Oncology, LLC
- National Heart, Lung, and Blood Institute (NHLBI)
- Case Western Reserve University
- Emory University
- University of Washington
- Johns Hopkins University
- North Central Cancer Treatment Group
- Thomas Jefferson University
- University of Michigan
- University of Rochester
- Mayo Clinic
- University of Minnesota
- City of Hope National Medical Center
- University of Texas at Houston
- Yeshiva University
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (1)